Patents by Inventor Weijie JI

Weijie JI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12286389
    Abstract: A crystalline form A of 2,2-bis(4-fluorophenyl)-2-phenylacetamide is provided. The crystalline form has good light stability, high temperature stability, and high humidity stability.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: April 29, 2025
    Assignee: SHENZHEN JINGTAI TECHNOLOGY CO., LTD
    Inventors: Guobin Ren, Dongxu Yi, Weijie Ji, Jiajun Huang
  • Patent number: 12268689
    Abstract: Disclosed are eutectic form A of Elagolix and pyrimethamine, a preparation method therefor and a use thereof. Using Cu-K? radiation, eutectic form A has characteristic peaks represented by a 2? degree at 8.1±0.2°, 12.2±0.2°, 13.3±0.2° and 21.1±0.2° in an X-ray powder diffraction. Eutectic form A has a high purity, a good light radiation stability, a high temperature stability, a high humidity stability and an accelerated stability, is easy to store, and has a slow moisture absorption under the condition of relatively low humidity, wherein the weight gain of eutectic form A by moisture absorption is not more than 1.08% when the relative humidity increases from 0 to 60% RH. Production conditions for eutectic form A are easy to control, same has a simple preparation process and a stable quality, and is easy to industrially produce on a large-scale.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: April 8, 2025
    Assignee: SHENZHEN JINGTAI TECHNOLOGY CO., LTD
    Inventors: Guobin Ren, Weijie Ji, Dongxu Yi, Jiajun Huang
  • Patent number: 12122804
    Abstract: A crystal form X of 3?-hydroxy-3?-methyl-21-(4-cyano-1H-pyrazol-1?-yl)-19-nor-5?-pregnan-20-one, a preparation method of said crystal form and an application thereof in preparing a drug for treatment of central nervous system disease.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: October 22, 2024
    Assignee: SHENZHEN RENTAI PHARMATECH LTD.
    Inventors: Guobin Ren, Weijie Ji, Dongxu Yi, Jiajun Huang
  • Publication number: 20220169658
    Abstract: Provided are a crystal form of a gonadotropin releasing hormone antagonist, a preparation method therefor, and use thereof. A crystal form C and a crystal form D have high purity, good illumination stability, high temperature stability, and high humidity stability, and have good solubility and low hygroscopicity; the saturation solubility of the crystal form C and the crystal form D is 101.75 ?g/ml and 87.21 ?g/ml, respectively; when the relative humidity is increased from 0 to 50% RH, the hygroscopy gain of the crystal form C and the crystal form D is not greater than 1.76% and 0.73%, respectively; and when the relative humidity is increased from 0 to 90% RH, the hygroscopy gain of the crystal form C and the crystal form D is not greater than 3.43% and 1.61%, respectively. Therefore, the control of a production condition is facilitated, the preparation process is simple, the quality is stable, and large-scale industrial production is easy.
    Type: Application
    Filed: February 18, 2022
    Publication date: June 2, 2022
    Inventors: Guobin Ren, Weijie Ji, Dongxu Yi, Jiajun Huang
  • Publication number: 20220169619
    Abstract: Disclosed is crystal form M of the proline hydroxylase inhibitor daprodustat, wherein the X-ray powder diffraction thereof, expressed in 2? angles and using Cu-Ka radiation, has characteristic peaks at 4.7±0.2°, 6.5±0.2°, and 6.8±0.2°. Disclosed are the preparation method for and the use of crystal form M. The crystal form M has good light stability, high temperature stability and high humidity stability, good solubility, and high purity.
    Type: Application
    Filed: February 18, 2022
    Publication date: June 2, 2022
    Inventors: Guobin Ren, Weijie Ji, Dongxu Yi, Jiajun Huang
  • Publication number: 20220143019
    Abstract: Disclosed are eutectic form A of Elagolix and pyrimethamine, a preparation method therefor and a use thereof. Using Cu-K? radiation, eutectic form A has characteristic peaks represented by a 20 degree at 8.1±0.2°, 12.2±0.2°, 13.3±0.2° and 21.1±0.2° in an X-ray powder diffraction. Eutectic form A has a high purity, a good light radiation stability, a high temperature stability, a high humidity stability and an accelerated stability, is easy to store, and has a slow moisture absorption under the condition of relatively low humidity, wherein the weight gain of eutectic form A by moisture absorption is not more than 1.08% when the relative humidity increases from 0 to 60% RH. Production conditions for eutectic form A are easy to control, same has a simple preparation process and a stable quality, and is easy to industrially produce on a large-scale.
    Type: Application
    Filed: January 27, 2022
    Publication date: May 12, 2022
    Inventors: Guobin Ren, Weijie Ji, Dongxu Yi, Jiajun Huang
  • Publication number: 20220098230
    Abstract: A crystal form X of 3?-hydroxy-3?-methyl-21-(4-cyano-1H-pyrazol-1?-yl)-19-nor-5?-pregnan-20-one, a preparation method of said crystal form and an application thereof in preparing a drug for treatment of central nervous system disease.
    Type: Application
    Filed: January 31, 2019
    Publication date: March 31, 2022
    Inventors: Guobin Ren, Weijie Ji, Dongxu YI, Jiajun Huang
  • Publication number: 20220033355
    Abstract: A crystal form A of 2-(2, 5-dioxopyrrolidin-1yl)ethyl methyl fumarate has a good light irradiation stability, high-temperature stability and high-humidity stability.
    Type: Application
    Filed: September 28, 2021
    Publication date: February 3, 2022
    Inventors: Guobin REN, Dongxu YI, Weijie JI, Jiajun HUANG
  • Publication number: 20220033347
    Abstract: A crystalline form A of 2,2-bis(4-fluorophenyl)-2-phenylacetamide is provided. The crystalline form has good light stability, high temperature stability, and high humidity stability.
    Type: Application
    Filed: September 28, 2021
    Publication date: February 3, 2022
    Inventors: Guobin REN, Dongxu YI, Weijie JI, Jiajun HUANG